TY - JOUR
T1 - Antimicrobial and anti-inflammatory activities of endophytic fungi Talaromyces wortmannii extracts against acne-inducing bacteria
AU - Pretsch, A.
AU - Nagl, M.
AU - Schwendinger, K.
AU - Kreiseder, B.
AU - Wiederstein, M.
AU - Pretsch, D.
AU - Genov, M.
AU - Hollaus, R.
AU - Zinssmeister, D.
AU - Debbab, A.
AU - Hundsberger, H.
AU - Eger, A.
AU - Proksch, P.
AU - Wiesner, C.
N1 - cited By 46
PY - 2014/6/2
Y1 - 2014/6/2
N2 - Acne vulgaris is the most common skin disease, causing significant psychosocial problems such as anxiety and depression similar to a chronic illness for those afflicted. Currently, obtainable agents for acne treatment have limited use. Thus, development of novel agents to treat this disease is a high medical need. The anaerobic bacterium Propionibacterium acnes has been implicated in the inflammatory phase of acne vulgaris by activating pro-inflammatory mediators such as the interleukin-8 (IL-8) via the NF-κB and MAPK pathways. Talaromyces wortmannii is an endophytic fungus, which is known to produce high bioactive natural compounds. We hypothesize that compound C but also the crude extract from T. wortmannii may possess both antibacterial activity especially against P. acnes and also anti-inflammatory properties by inhibiting TNF-α-induced ICAM-1 expression and P. acnes-induced IL-8 release. Treatment of keratinocytes (HaCaT) with P. acnes significantly increased NF-κB and activator protein-1 (AP-1) activation, as well as IL-8 release. Compound C inhibited P. acnes -mediated activation of NF-κB and AP-1 by inhibiting IκB degradation and the phosphorylation of ERK and JNK MAP kinases, and IL-8 release in a dose-dependent manner. Based on these results, compound C has effective antimicrobial activity against P. acnes and anti-inflammatory activity, and we suggest that this substance or the crude extract are alternative treatments for antibiotic/anti-inflammatory therapy for acne vulgaris.
AB - Acne vulgaris is the most common skin disease, causing significant psychosocial problems such as anxiety and depression similar to a chronic illness for those afflicted. Currently, obtainable agents for acne treatment have limited use. Thus, development of novel agents to treat this disease is a high medical need. The anaerobic bacterium Propionibacterium acnes has been implicated in the inflammatory phase of acne vulgaris by activating pro-inflammatory mediators such as the interleukin-8 (IL-8) via the NF-κB and MAPK pathways. Talaromyces wortmannii is an endophytic fungus, which is known to produce high bioactive natural compounds. We hypothesize that compound C but also the crude extract from T. wortmannii may possess both antibacterial activity especially against P. acnes and also anti-inflammatory properties by inhibiting TNF-α-induced ICAM-1 expression and P. acnes-induced IL-8 release. Treatment of keratinocytes (HaCaT) with P. acnes significantly increased NF-κB and activator protein-1 (AP-1) activation, as well as IL-8 release. Compound C inhibited P. acnes -mediated activation of NF-κB and AP-1 by inhibiting IκB degradation and the phosphorylation of ERK and JNK MAP kinases, and IL-8 release in a dose-dependent manner. Based on these results, compound C has effective antimicrobial activity against P. acnes and anti-inflammatory activity, and we suggest that this substance or the crude extract are alternative treatments for antibiotic/anti-inflammatory therapy for acne vulgaris.
KW - antiinfective agent
KW - antiinflammatory agent
KW - doxycycline
KW - erythromycin
KW - fungal extract
KW - I kappa B kinase beta
KW - immunoglobulin enhancer binding protein
KW - intercellular adhesion molecule 1
KW - interleukin 8
KW - minocycline
KW - mitogen activated protein kinase
KW - stress activated protein kinase
KW - Talaromyces wortmannii extract
KW - transcription factor AP 1
KW - unclassified drug
KW - biological product
KW - drug mixture
KW - tumor necrosis factor alpha
KW - antibacterial activity
KW - antiinflammatory activity
KW - article
KW - concentration response
KW - controlled study
KW - cytokine release
KW - cytotoxicity assay
KW - drug mechanism
KW - enzyme degradation
KW - human
KW - human cell
KW - minimum inhibitory concentration
KW - nonhuman
KW - Propionibacterium acnes
KW - Talaromyces
KW - Talaromyces wortmannii
KW - acne vulgaris
KW - cell death
KW - cell line
KW - chemistry
KW - drug effects
KW - drug screening
KW - endophyte
KW - enzyme activation
KW - high performance liquid chromatography
KW - isolation and purification
KW - mass spectrometry
KW - metabolism
KW - microbial sensitivity test
KW - microbiology
KW - pharmacology
KW - physiology
KW - Acne Vulgaris
KW - Anti-Bacterial Agents
KW - Anti-Inflammatory Agents
KW - Biological Products
KW - Cell Death
KW - Cell Line
KW - Chromatography
KW - High Pressure Liquid
KW - Complex Mixtures
KW - Drug Evaluation
KW - Preclinical
KW - Endophytes
KW - Enzyme Activation
KW - Humans
KW - Intercellular Adhesion Molecule-1
KW - Interleukin-8
KW - Mass Spectrometry
KW - Microbial Sensitivity Tests
KW - Mitogen-Activated Protein Kinases
KW - NF-kappa B
KW - Tumor Necrosis Factor-alpha
KW - Biological Products/isolation & purification
KW - Complex Mixtures/pharmacology
KW - Interleukin-8/metabolism
KW - Endophytes/chemistry
KW - Cell Death/drug effects
KW - Enzyme Activation/drug effects
KW - Tumor Necrosis Factor-alpha/pharmacology
KW - Propionibacterium acnes/drug effects
KW - NF-kappa B/metabolism
KW - Intercellular Adhesion Molecule-1/metabolism
KW - Chromatography, High Pressure Liquid
KW - Anti-Bacterial Agents/pharmacology
KW - Talaromyces/chemistry
KW - Drug Evaluation, Preclinical
KW - Acne Vulgaris/microbiology
KW - Anti-Inflammatory Agents/pharmacology
KW - Mitogen-Activated Protein Kinases/metabolism
UR - http://www.scopus.com/inward/record.url?scp=84902349990&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0097929
DO - 10.1371/journal.pone.0097929
M3 - Article
C2 - 24887557
SN - 1932-6203
VL - 9
SP - e97929
JO - PLoS ONE
JF - PLoS ONE
IS - 6
M1 - e97929
ER -